Advertisement
Organisation › Details
Aboleris Pharma (FR)
AbolerIS Pharma is a pioneering biopharmaceutical company focused on revolutionizing immunotherapy for autoimmune and inflammatory diseases. Through innovative antibody therapy targeting CD45RC, AbolerIS Pharma aims to restore immune balance and achieve long-lasting remission for patients with conditions such as rheumatoid arthritis. Led by a team of reputable scientists, AbolerIS Pharma translates groundbreaking discoveries into tangible therapies, with an unwavering dedication to addressing patients’ needs. *
Start | 2023-09-21 existent | |
Predecessor | University of Nantes (Université de Nantes) | |
Industry | BIOTECH | |
Industry 2 | anti-CD45RC antibody | |
Region | Nantes | |
Country | France | |
Street | 1 Rue Gaston Veil | |
City | 44000 Nantes | |
Address record changed: 2023-09-23 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Aboleris Pharma. (9/18/23). "Press Release: Aboleris Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases". Gosselies. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Aboleris Pharma (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top